EcoCRM、病毒样颗粒与mRNA作为伯氏疏螺旋体疫苗平台的评价
莱姆病在美国每年影响约476,000人,现有预防依赖个人防护措施,亟需疫苗。本研究以非脂化OspA为模型抗原,在C3H小鼠中比较EcoCRM OspA、OspA-SpyVLP和OspA mRNA三种疫苗平台的免疫原性与保护效果。结果显示三种疫苗均具免疫原性且诱导相似水平抗原特异性IgG,但平台间在抗体分泌细胞、IgG1/IgG2亚类比例和抗体亲和力上存在显著差异;OspA-SpyVLP血清体外杀螺旋体活性最高,比重组OspA高16倍。
要点
- 三种OspA疫苗平台均诱导相似水平血清抗原特异性IgG。
- 加强免疫后约两周,平台间抗体分泌细胞、IgG亚类比例和亲和力差异显著。
- OspA-SpyVLP血清体外杀螺旋体活性比重组OspA高16倍。
核心结论
- 疫苗平台/配方的选择影响OspA基莱姆病疫苗的免疫原性和效力,开发时应予以考虑。
研究设计与样本
- 在C3H小鼠中使用针头注射攻毒模型,比较EcoCRM OspA、OspA-SpyVLP和OspA mRNA三种疫苗平台。
主要发现
- 所有疫苗配方均具免疫原性,实验期间诱导相似水平的血清抗原特异性IgG。
- 加强免疫后约两周,平台间在抗体分泌细胞存在、IgG1/IgG2亚类比例和抗体亲和力方面存在显著差异。
- 重组非脂化OspA和OspA-SpyVLP疫苗接种显著减少攻毒后阳性器官数量,与PBS对照相比。
- OspA-SpyVLP血清体外杀螺旋体活性最高,滴度比重组OspA高16倍。
临床怎么用
- 莱姆病疫苗开发中应评估不同平台对免疫原性和保护效力的影响,而非仅关注抗原本身。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lyme disease (LD) is the most prevalent vector-borne disease in the United States, impacting ∼476,000 individuals annually with increasing incidence. Prevention relies on personal protective measures such as insecticides and tick checks, underscoring the need for new preventatives such as vaccines. In this work, the importance of vaccine platform in LD vaccine development efforts was evaluated using non-lipidated OspA as model antigen. Recombinant OspA conjugated to CRM197 (EcoCRM OspA), a virus-like particle vaccine utilizing SpyTag and SpyCatcher (OspA-SpyVLP), and an mRNA-based vaccine construct (OspA mRNA) were evaluated and compared in C3H mice using the needle injection challenge model. To determine immunogenicity, anti-OspA and anti-B. burgdorferi antibodies were quantified via ELISA and further assessed by measuring IgG subclass, antibody avidity, and presence of antibody secreting cells. All vaccine formulations were immunogenic and led to the release of similar levels of antigen-specific IgG in serum during the duration of the experiment. However, there were significant differences around two week post-boost in the presence of antibody secreting cells, ratio of IgG1/IgG2 subclasses, and antibody avidity between platforms. Protection was measured using PCR and darkfield microscopy to determine organ positivity post-challenge. Vaccination with recombinant non-lipidated OspA and OspA-SpyVLP significantly reduced the number of positive organs compared to the PBS challenged control group. Lastly, in vitro borreliacidal activity was quantified via darkfield microscopy and the highest borreliacidal activity was observed using OspA-SpyVLP sera, with titers 16-fold higher than recombinant OspA. Altogether, these data indicated that selection of vaccine platform/formulation influenced the immunogenicity and efficacy of OspA-based LD vaccines and should be considered during development.
引用
- Rocuskie-Marker CM, Huckaby AB, Conaway OM, et al. Evaluation of EcoCRM, virus-like particles, and mRNA as vaccine platforms against Borrelia burgdorferi. Vaccine. 2026. PMID: 42176436. doi:10.1016/j.vaccine.2026.128696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。